Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Exenatide in combination therapy: small study, big market, and many unanswered questions.

Malozowski S.

Ann Intern Med. 2007 Apr 3;146(7):527-8. No abstract available.

PMID:
17404355
2.

Summaries for patients. Exenatide therapy for type 2 diabetes.

[No authors listed]

Ann Intern Med. 2007 Apr 3;146(7):I18. No abstract available.

PMID:
17404346
3.

Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?

[No authors listed]

Ann Intern Med. 2011 Jan 18;154(2):I-40. doi: 10.7326/0003-4819-154-2-201101180-00301. Epub 2010 Dec 6. No abstract available.

PMID:
21135289
4.

The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.

Zinman B, Hoogwerf BJ, Durán García S, Milton DR, Giaconia JM, Kim DD, Trautmann ME, Brodows RG.

Ann Intern Med. 2007 Apr 3;146(7):477-85. Erratum in: Ann Intern Med. 2007 Jun 19;146(12):896.

PMID:
17404349
5.

Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.

Norwood P, Liutkus JF, Haber H, Pintilei E, Boardman MK, Trautmann ME.

Clin Ther. 2012 Oct;34(10):2082-90. doi: 10.1016/j.clinthera.2012.09.007. Epub 2012 Sep 29.

PMID:
23031623
6.

Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus.

Ryan GJ, Moniri NH, Smiley DD.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1123-31. doi: 10.2146/ajhp120168. Review.

PMID:
23784159
7.

An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.

Painter NA, Morello CM, Singh RF, McBane SE.

J Am Board Fam Med. 2013 Mar-Apr;26(2):203-10. doi: 10.3122/jabfm.2013.02.120174.

8.

[Type 2 diabetic patient with reduced beta-cell function. New substance class: incretin-mimetics].

[No authors listed]

MMW Fortschr Med. 2005 Aug 4;147(31-32):55. German. No abstract available.

PMID:
16128203
9.

Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial.

Buse JB, Bergenstal RM, Glass LC, Heilmann CR, Lewis MS, Kwan AY, Hoogwerf BJ, Rosenstock J.

Ann Intern Med. 2011 Jan 18;154(2):103-12. doi: 10.7326/0003-4819-154-2-201101180-00300. Epub 2010 Dec 6.

PMID:
21138825
10.

Exenatide and acute pancreatitis.

Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A.

J Assoc Physicians India. 2008 Dec;56:987-8.

PMID:
19322980
13.

Exenatide once weekly in type 2 diabetes.

Scheen AJ.

Lancet. 2008 Oct 4;372(9645):1197-8. doi: 10.1016/S0140-6736(08)61207-6. Epub 2008 Sep 7. No abstract available.

PMID:
18782642
14.

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.

Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V; NovoLog Mix-vs.-Exenatide Study Group.

Curr Med Res Opin. 2009 Jan;25(1):65-75. doi: 10.1185/03007990802597951 .

PMID:
19210140
15.

Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus.

Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, Brodows RG, Kim DD.

Diabetes Obes Metab. 2006 Jul;8(4):419-28.

PMID:
16776749
16.

Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!

Rosenstock J, Fonseca V.

Diabetes Care. 2007 Nov;30(11):2972-3. No abstract available.

PMID:
17965313
17.

Time for clinically relevant comparative effectiveness studies in type 2 diabetes.

Nathan DM.

Ann Intern Med. 2011 Jan 18;154(2):131-2. doi: 10.7326/0003-4819-154-2-201101180-00303. Epub 2010 Dec 6. No abstract available.

PMID:
21135287
18.

Exenatide (Byetta) for type 2 diabetes.

[No authors listed]

Med Lett Drugs Ther. 2005 Jun 6;47(1210):45-6.

PMID:
15933616
19.

Drugs for diabetes.

Abramowicz M, Zuccotti G; Medical Letter.

Treat Guidel Med Lett. 2005 Aug;3(36):57-62. No abstract available.

PMID:
16012392
20.

Type 2 diabetes: the end of clinical inertia.

Mirza SA.

South Med J. 2007 Aug;100(8):765-6. No abstract available.

PMID:
17713297

Supplemental Content

Support Center